CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
Published on February 17, 2009
February 16, 2009
Via EDGAR
Mr. Jay Webb
Reviewing Accountant
Division of Corporate Finance
United States Securities and Exchange Commission
Mail Stop 3030
Washington, D.C. 20549
Reviewing Accountant
Division of Corporate Finance
United States Securities and Exchange Commission
Mail Stop 3030
Washington, D.C. 20549
Re: | OPKO Health, Inc. Form 10-K for the year ended December 31, 2007 Filed March 31, 2008 File No. 001-33528 |
Dear Mr. Webb:
We received comments from the Staff of the Division of Corporation Finance (the Staff) of the
Securities and Exchange Commission (the SEC) dated February 4, 2009, regarding the Form 10-K for
the fiscal year ended December 31, 2007 (Form 10-K) of OPKO Health, Inc. (the Company). We
appreciate your comments and have reviewed them carefully. This letter responds to the Staffs
comments. For convenience, we have included the Staffs comments in italics before each of the
Companys responses. References in our responses to we, our or us mean the Company.
Form 10-K for the Year Ended December 31, 2007
Financial Statements page 50
Note 1 Business and Organization, page 56
1. Please refer to our prior comment 1. We note from your response that the Frost Group only
controlled 41% of the voting shares of eXegenics and this fact is one of the reasons you concluded
the merger between eXegenics and Froptix was not a merger of entities under common control. Please
tell us how you determined the 41% ownership level and the date at which this was determined.
Please also reconcile this calculation with your disclosure on page 56 of your Form 10-K that on
February 9, 2007 eXegenics completed the sale of approximately 19.4 million shares of its common
stock, constituting 51% of its issued and outstanding shares of capital stock to a small group of
investors led by the Frost Group. Finally, revise future filings to include the significant
information outlined in your response.
OPKO Health, Inc.
Page 2
Page 2
Response
The 41% ownership level of the Frost Group is determined by calculating the number of shares held
by the Frost Group divided by the number of shares outstanding after the shares were issued on
February 9, 2007. As disclosed, the sale of eXegenics shares was made to a small group of
investors. The Frost Group was the largest investor in this transaction, acquiring 15.5 million of
the 19.4 million shares issued. Other investors unrelated to the Frost Group also participated and
purchased shares from eXegenics. It should be noted that the shareholdings at the time of the
merger, March 27, 2007 had not changed for the Frost Group.
In future filings, we will disclose the number of shares purchased by The Frost Group in the
February 2007 transaction.
2. In this regard, please also tell us about The Frost Groups ownership of Acuity immediately
prior to the March 2007 merger.
Response
The Frost Group held a total of 15,625 Warrants to acquire Acuity Common Stock and 125,000 Warrants
to Acquire Acuity Series B Preferred Stock, representing less than 1% of Acuitys fully diluted
shares outstanding on an as converted basis immediately prior to the merger. These instruments
were issued in connection with the line of credit between the Frost Group and Acuity on January 11,
2007. The Frost Group held no other equity interest in Acuity prior to the March 2007 merger.
Note 2 Acquisitions, page 56
3. Please refer to our prior comment 3. Please confirm you will revise future filings to provide
the enhanced disclosure that you provided in your response.
Response
We will enhance our future filings to include the additional disclosure in the Notes to our
Financial Statements.
Note 5 Debt, page 61
4. Please refer to our prior comment 4. Please provide us with authoritative GAAP literature that
supports your accounting. In addition, please further explain to us how you determined the amount
that you allocated to the cost of the Acuity transaction ($1.3 million), the cost of the reverse
merger between Froptix and eXegenics ($11.0 million)
OPKO Health, Inc.
Page 3
Page 3
and debt commitment fee ($0.1 million) and why. We are especially interested why any costs
associated with the warrants would properly be allocated to the costs of the reverse merger.
Response
The warrants that were issued to the Frost Group were issued in connection with expansion and
extension of the line of credit and were only issuable in the event both the business combination
(the acquisition of Acuity) and the transaction whereby Froptix became a public company (the
reverse merger between Froptix and eXegenics) occurred.
We were unable to locate any direct authoritative literature regarding allocating the costs of
warrants issued only in the event that three different transactions occur (line of credit, business
combination and reverse merger); however, support for the concept of allocating common costs over
separate transactions exists in SAB 77, which indicates that fees paid to an investment banker in
connection with a transaction to be accounted for as a business combination for providing interim
financing or underwriting services must be allocated between direct costs of the acquisition and
debt issue costs. Authoritative literature does exist for each of the transactions that had to
occur for the warrants to be issued as follows:
1. Cost of obtaining a line of credit Accounting Principal Board Opinion (APB)
21, Interest on Receivables and Payables
2. Cost of consummating a business combination Financial Accounting Standards
No. 141, Business Combinations
3. Cost of reverse merger November 16, 1998 SEC Communication
We based our allocation of the warrant cost to each component on the relative fair value of each
transaction and believe it is consistent with the concepts in SAB 77 and results in an appropriate
allocation of the warrant costs to the transactions impacted by their issuance.
Sincerely, |
||||
/s/ Rao Uppaluri | ||||
Rao Uppaluri | ||||
Senior Vice President and Chief Financial Officer | ||||
Copy: Julie Sherman, Staff Accountant